BIOCRYST PHARMACEUTICALS, INC. Gain (Loss) on Disposition of Assets
BIOCRYST PHARMACEUTICALS, INC. (BCRX) reported Gain (Loss) on Disposition of Assets of -$7.00 thousand for the 12-month period ending 2018-12-31, per its 10-K filed 2019-03-14.
Discontinued › Income Statement › Other Income
us-gaap:GainLossOnDispositionOfAssets1 · last filed 2019-03-14
- BIOCRYST PHARMACEUTICALS, INC. gain (loss) on disposition of assets for the quarter ending 2016-12-31 was $4.00K.
- BIOCRYST PHARMACEUTICALS, INC. gain (loss) on disposition of assets for the quarter ending 2013-12-31 was $0.00.
- BIOCRYST PHARMACEUTICALS, INC. gain (loss) on disposition of assets for fiscal 2018 was -$7.00K, a 158.33% decline from fiscal 2017.
- BIOCRYST PHARMACEUTICALS, INC. gain (loss) on disposition of assets for fiscal 2017 was $12.00K.
- BIOCRYST PHARMACEUTICALS, INC. gain (loss) on disposition of assets for fiscal 2016 was -$17.00K.
- BIOCRYST PHARMACEUTICALS, INC. gain (loss) on disposition of assets for fiscal 2014 was -$27.00K, a 157.45% decline from fiscal 2013.
| Period end | Gain (Loss) on Disposition of Assets 3 month | Gain (Loss) on Disposition of Assets 9 month | Gain (Loss) on Disposition of Assets 12 month |
|---|---|---|---|
| 2018-12-31 | -$7.00K 10-K · filed 2019-03-14 | ||
| 2017-12-31 | $12.00K 10-K · filed 2019-03-14 | ||
| 2016-12-31 | $4.00K derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-14 | -$17.00K 10-K · filed 2019-03-14 | |
| 2016-09-30 | -$21.00K 10-Q · filed 2017-11-08 | ||
| 2014-12-31 | -$27.00K 10-K · filed 2017-02-27 | ||
| 2013-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2016-02-26 | $47.00K 10-K · filed 2016-02-26 | |
| 2013-09-30 | $47.00K 10-Q · filed 2014-11-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 |